Plain-English translation of NCT06397027 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a combination of three medications — , , and — in children and young adults (ages 2–21) whose acute leukemia has returned or is no longer responding to standard treatment. The study will first determine what dose is safest and most effective, then test how well this combination works. Researchers hope this approach may help children whose leukemia has specific genetic mutations that make their disease particularly hard to treat.
Children with relapsed or refractory leukemia have very limited treatment options and poor survival rates. This medication combination targets specific genetic changes found in these hard-to-treat leukemias, offering hope for a new approach when standard treatments have failed.
You likely qualify if…
You likely don't qualify if…
You would take three oral medications (pills) as part of a carefully monitored treatment plan. The study starts with a small group of patients at a lower dose to make sure it is safe; if tolerated well, future groups may receive higher doses. You would have regular clinic visits for blood tests, physical exams, and imaging to check how you are responding and watch for side effects. The exact length and schedule of treatment would depend on your individual situation and how you respond.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
M.D. Anderson Cancer Center
Collaborators
Kura Oncology, Inc.
Enrollment target
~22 participants
Started
December 2024
Primary completion
December 2028
Age range
2 Years – 21 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
David McCall, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.